Clinical Trials Browser

Recruiting × Urinary Bladder Neoplasms × Radiotherapy, Intensity-Modulated × Clear all

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

Urinary Bladder Neoplasms